Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 11/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326604 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PRKCIMEN1 | |
| SCHEMBL13326607 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PRKCIMEN1 | |
| SCHEMBL4704528 | 0.91 | HRH3 (0.44) | CHRM2CHRM1CHRM3PRKCIMEN1 | |
| SCHEMBL28198370 | 0.81 | — | — | |
| SCHEMBL12574025 | 0.78 | MEN1 (0.57) | MEN1TSHRKMT2A | |
| SCHEMBL5112007 | 0.77 | TSHR (0.59) | MEN1TSHRKMT2A | |
| SCHEMBL13326564 | 0.75 | HRH4 (0.41) | PRKCIBRD4ATAD2HRH4HRH3 | |
| SCHEMBL13326560 | 0.75 | CYP1A2 (0.39) | PRKCITSHRHRH4HRH3HRH2 | |
| SCHEMBL13326519 | 0.74 | CYP3A4 (0.47) | CHRM2CHRM1CHRM3PRKCIBRD4 | |
| SCHEMBL12120470 | 0.74 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PRKCIHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030557-B1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | IDIENCE CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | disclosed |
| WO-2022237649-A1 | EXOCYCLIC AMINO QUINAZOLINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-12-19 | — | — | US | disclosed |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2017-06-29 | — | — | US | disclosed |
| US-9682973-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-06-20 | — | — | US | disclosed |
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2016-08-04 | — | — | US | disclosed |
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1968957-B1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2007079960-A9 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| EP-1968957-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079960-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, PARP1 | CHRM2 4784/4885CHRM1 4793/4885CHRM3 4488/4885 |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, NUDT5 | CHRM2 4769/4885CHRM1 4782/4885CHRM3 4502/4885 |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, SLC5A2, DPP4 | CHRM2 3573/4885CHRM1 4005/4885CHRM3 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.